Page 193 - Memoria SEHH 2022

MEMORIA ANUAL 2022 SOCIEDAD ESPAÑOLA DE
HEMATOLOGÍA Y HEMOTERAPIA
GELMC
FUNDACIÓN ESPAÑOLA DE HEMATOLOGÍA Y HEMOTERAPIA
• Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequen- cing of genomic DNA.
Sci Rep. 2022 Jul 29;12(1):13057. doi: 10.1038/s41598-022-17271-3.
Sánchez R, Dorado S, Ruíz-Heredia Y, Martín-Muñoz A, Rosa-Rosa JM, Ribera J, García O, Jiménez-Ubieto A, Carreño-Tarragona G, Linares M, Rufián L, Juárez A, Carrillo J, Espino MJ, Cáceres M, Expósito S, Cuevas B, Vanegas R, Casado LF, Torrent A, Zamora L, Mer- cadal S, Coll R, Cervera M, Morgades M, Hernández-Rivas JÁ, Bravo P, Serí C, Anguita E, Barragán E, Sargas C, Ferrer-Marín F, Sánchez-Calero J, Sevilla J, Ruíz E, Villalón L, Del Mar Herráez M, Riaza R, Magro E, Steegmann JL, Wang C, de Toledo P, García-Gutiérrez V, Ayala R, Ribera JM, Barrio S, Martínez-López J .
• Tyrosine kinase inhibitor dose reduction during the management of accelerated phase chronic myeloid leukemia.
Leuk Res. 2022 Oct;121:106923. doi: 10.1016/j.leukres.2022.106923.
Ortí G, García-Gutiérrez V, Bautista G, Ferrer-Marín F, Vallansot R, Xicoy B, Sánchez À, Simón I, Triguero A, Sierra M, Casado LF; Grupo Español de Leucemia Mieloide Crónica (GELMC) .
Comunicaciones orales
Congresos internacionales
• Thrombogenesis mechanisms of high doses of ponatinib in patients with chronic myeloid leukemia (CML) compared to tyrosine kinase inhibitors.
64th American Society of Hematology (ASH) Annual Meeting and Exposition. New Orleans (USA), 10-13 de diciembre de 2022.
Águila S, Cuenca EJ, Lys MJ, García-Hernández C, Fernández MJ, Noya M, García Gu- tiérrez V, Palomera L, Senín A, Pérez López R, Pérez-Encinas M, Angona A, Puerta JM, Vallansot R, Conesa V, Hernández Boluda JC, Rosell A, Cortes M, Ortí G, Xicoy B, Ca- rreño G, Mora Castera E, Giraldo P, Lozano ML, Casado LF, Ferrer Marín F; on Behalf Of Gelmc .
• Real-World Data Analysis of the Molecular Response Kinetics within the Two First Years of the RELMC-NOVA Study in Newly Diagnosed Spanish CML-CP Patients Trea- ted with Tirosin Kinasa Inhibitors (TKIs) in First Line.
64th American Society of Hematology (ASH) Annual Meeting and Exposition. New Orleans (USA), 10-13 de diciembre de 2022.
193